NCT05771883View on ClinicalTrials.gov

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

November 30, 2025

Conditions

B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG

IMM0306

IMM0306 is a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα. The Fc segment of the recombinant protein in IMM0306 is IgG1 and has been modified by ADCC-enhanced genetic engineering.

DRUG

Lenalidomide capsule

Chemical name 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidin-2,6-dione, molecular formula C 13H 13 N 3 O 3, is an anti-tumor drug developed by Celgene Biopharmaceutical Company in the United States, with multiple effects such as anti-tumor, immunomodulatory and anti-angiogenesis

All Listed Sponsors

lead

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

OTHER

NCT05771883 - A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide | Biotech Hunter | Biotech Hunter